Amitiza Related Published Studies
Well-designed clinical trials related to Amitiza (Lubiprostone)
Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. [2011.06]
Efficacy and safety of lubiprostone in patients with chronic constipation. [2010.04]
Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. [2009.11]
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. [2009.02.01]
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. [2009.02]
Single-dose lubiprostone along with split-dose PEG solution without dietary restrictions for bowel cleansing prior to colonoscopy: a randomized, double-blind, placebo-controlled trial. [2008.09]
Single-Dose Lubiprostone Along With Split-Dose PEG Solution Without Dietary Restrictions for Bowel Cleansing Prior to Colonoscopy: A Randomized, Double-Blind, Placebo-Controlled Trial. [2008.08.05]
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. [2008.04]
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. [2008.01]
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. [2007.06.01]
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. [2006.05]
Well-designed clinical trials possibly related to Amitiza (Lubiprostone)
MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies. [2011.04]
Other research related to Amitiza (Lubiprostone)
A critical appraisal of lubiprostone in the treatment of chronic constipation in
the elderly. [2013]
Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. [2011.10]
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. [2011.09]
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. [2011.06]
Lubiprostone for the treatment of opioid-induced bowel dysfunction. [2011.04]
Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. [2011.02]
Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. [2010.10.27]
Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype. [2010.09.15]
Lubiprostone used with polyethylene glycol in diabetic patients enhances colonoscopy preparation quality. [2010.07.16]
Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. [2010.07]
Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series. [2010.03]
Efficacy and safety of lubiprostone in patients with chronic constipation. [2010]
Lubiprostone: in constipation-predominant irritable bowel syndrome. [2009.06.18]
Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. [2009.04]
Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. [2009.01]
Lubiprostone: in constipation-predominant irritable bowel syndrome. [2009]
Lubiprostone for constipation and irritable bowel syndrome with constipation. [2008.12]
Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. [2008.11]
Lubiprostone--a novel treatment for irritable bowel syndrome with constipation. [2008.09]
Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders. [2008.08]
Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. [2008.08]
Lubiprostone: a novel treatment for chronic constipation. [2008]
Lubiprostone: a new drug for the treatment of chronic idiopathic constipation. [2007.09]
Lubiprostone: a chloride channel activator for treatment of chronic constipation. [2007.06]
Lubiprostone: a chloride channel activator. [2007.04]
Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. [2007.02]
Lubiprostone: chloride channel activator for chronic constipation. [2006.12]
Lubiprostone. [2006]
Lubiprostone. [2005.05]
Other possibly related research studies
Development of drugs for gastrointestinal motor disorders: translating science to clinical need. [2008.03]
Gateways to clinical trials. [2007.11]
Constipation: evaluation and treatment of colonic and anorectal motility disorders. [2007.09]
Fresh perspectives in chronic constipation and other functional bowel disorders. [2007.06]
Cancer-related constipation. [2007.07]
Novel and alternative therapies for childhood constipation. [2007.06]
Constipation in long-term care. [2007.05]
New drugs 07, part I. [2007.02]
Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. [2007.01]
Gateways to clinical trials. [2006.09]
Defecation disorders: neuromuscular aspects and treatment. [2006.08]
Chronic constipation: let symptom type and severity direct treatment. [2006.07]
Gateways to clinical trials. [2006.01]
Gateways to clinical trials. [2005.05]
Gateways to clinical trials. [2003.07]
A synthetic prostone activates apical chloride channels in A6 epithelial cells. [2008.08]
Pathogenesis and management of irritable bowel syndrome. [2009.01]
Constipation in the elderly: management strategies. [2009]
Constipation: evaluation and treatment of colonic and anorectal motility disorders. [2009.01]
Pharmacologic treatment of constipation: what is new? [2008.12]
Enteric nervous system: sensory physiology, diarrhea and constipation. [2010.03]
Review article: new receptor targets for medical therapy in irritable bowel syndrome. [2010.01]
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. [2009.05]
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. [2011.06]
Treatment of irritable bowel syndrome. [2011.06]
Review article: the treatment of functional abdominal bloating and distension. [2011.05]
Current and future therapies for chronic constipation. [2011.02]
A review of laxative therapies for treatment of chronic constipation in older adults. [2010.12]
Peripherally acting therapies for the treatment of irritable bowel syndrome. [2011.03]
Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. [2011.02]
[New therapeutical approaches for treatment of irritable bowel syndrome]. [2010.08]
Pharmacologic management of chronic constipation. [2010.09]
Gastroduodenal mucosal defense. [2010.11]
Emerging pharmacologic therapies for irritable bowel syndrome. [2010.10]
[New drugs for the treatment of constipation]. [2010.07]
Linaclotide in the management of gastrointestinal tract disorders. [2012]
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. [2012]
Effect of laxatives and pharmacological therapies in chronic idiopathic
constipation: systematic review and meta-analysis. [2011]
New treatment targets for the management of irritable bowel syndrome. [2014]
Metabolic and toxicological considerations for the latest drugs used to treat
irritable bowel syndrome. [2013]
Clinical trials in irritable bowel syndrome: a review. [2013]
|